Pancreatic adenocarcinoma treated with surgical resection, toceranib phosphate and firocoxib in a dog: a case report
Artículo de investigación publicado en Veterinary Research Communications
8 de marzo de 2024
Exocrine pancreatic carcinomas are rarely reported in dogs. A ductal pancreatic adenocarcinoma in a 10-year-old intact beagle is described in this report. The diagnosis was made based on clinical signs, imaging (abdominal ultrasound and CT scan) and histopathology. Treatment consisted of partial right lobe pancreatectomy followed by adjuvant therapy with toceranib phosphate (Palladia®) and firocoxib (Previcox®) for six months. The treatment was well tolerated, and the survival time was 445 days. To our knowledge, this is the longest survival reported in the literature for a dog diagnosed with exocrine pancreatic adenocarcinoma. The results described here may contribute to provide a better understanding about this neoplasia and potential treatment options
Fuertes-Recuero M., Vazquez-Fernandez E., Lizasoain-Sanz G., Arroba-Alonso A., Sanchez-Lopez A., Martinez-de Merlo E., Suarez-Redondo M. y Ortiz-Diez G.
 | Departamento de Fisiología (Fisiología Animal). Departamento de Medicina y Cirugía Animal. Facultad de Veterinaria. Universidad Complutense (UCM). |
| Hospital Clínico Veterinario Complutense (HCVC). Universidad Complutense (UCM). |
| Servicio de Patología y Veterinaria Forense (SAP). Centro de Vigilancia Sanitaria Veterinaria (VISAVET). Universidad Complutense (UCM). |
